Clinical Trials on Pandemic H5N1 Influenza in United Kingdom

Total 1099 results

Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

United States, Australia, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Intercell USA, Inc.
Department of Health and Human Services

Completed

A/H5N1 Dose Ranging Study With Adjuvant Patch

Pandemic Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety Study of Avian Flu Vaccine

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | Orthomyxovirdae

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

H5N1 Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

H5N1 Influenza

United States
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Influenza A Virus, H5N1 Subtype

United States
Biomedical Advanced Research and Development Authority
PPD

Completed

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

A/Vietnam/H5N1 Influenza Virus

United States
IDRI
Defense Advanced Research Projects Agency; Medicago

Completed

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Influenza A Subtype H5N1 Infection

United States
PowderMed

Completed

Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu

Influenza (Pandemic)

United Kingdom
Hvivo
Pfizer

Completed

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

Influenza A H1N1

United Kingdom
Ology Bioservices

Completed

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

United States
SAb Biotherapeutics, Inc.
Hvivo

Active, not recruiting

Study of SAB-176 in Healthy Adult Participants

Influenza A H1N1

United Kingdom
University of Nottingham

Completed

Virus Shedding and Environmental Deposition of a Novel Influenza Virus

Novel (H1N1) Influenza

United Kingdom
St. Jude Children's Research Hospital

Completed

Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults

H1N1 Pandemic Flu

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Influenza

United States
GlaxoSmithKline

Completed

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza | Influenza Vaccines

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

Influenza

United States
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
VaxInnate Corporation

Completed

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Influenza

United States
VaxInnate Corporation

Completed

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Influenza

United States
GlaxoSmithKline
United States Department of Health and Human Services, Center for Disease...

Withdrawn

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza

United States
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response (HIPCVAX-010S)

Influenza A Subtype H5N1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1in Adult - Aventis

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

Influenza

United States
Centers for Disease Control and Prevention

Unknown

Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With AS03

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Inactivated Influenza A/H5N1 Vaccine in the Elderly

Influenza

United States
Sanofi

Completed

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

Influenza | Orthomyxoviridae Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 (Clade 2) Vaccination of Adults and Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Priming and Boosting Strategies

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

Influenza

United States
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada
Biomedical Advanced Research and Development Authority

Completed

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Influenza A Virus, H5N1 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With MF59

Influenza

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Influenza | Avian Influenza | H1N1 Influenza

United States
Virginia Commonwealth University

Completed

Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza

Seasonal Influenza | H1N1 Influenza

United States
BlueWillow Biologics
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Active, not recruiting

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults (IN-NE-rH5)

Influenza, Pandemic

United States
Novavax

Completed

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Pandemic Influenza

United States

Clinical Trials on Pandemic H5N1 Influenza in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations